Colorectal Cancer Drugs Treatments (surgical, chemotherapeutic, biologic, and radiation therapies); Regions ( Americas ,APAC ,EMEA )- Global Industrial Analysis, Growth, Trend and Forecast 2019
Colorectal
Cancer Drugs
Scope of the
Report:
1)
About this Report
Colorectal cancer refers to
malignancies that originate in the rectum or the colon. It is also known as
bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal
cancer. The cancer starts as a polyp in the inner wall of the colon or rectum.
These polyps can be benign or malignant. Colorectal cancer is the third most
common cancer in the US. Some of the risk factors that can cause colorectal
cancer are lifestyle changes, old age, genetic disorders, family history, and
inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood
in stool, decrease in appetite, constipation, weight loss, nausea, bloating,
and pelvic pain. Colorectal cancer can be classified into four broad stages.
Colorectal cancer can be treated using surgical, chemotherapeutic, biologic,
and radiation therapies .
Request
For Sample Report https://www.wiseguyreports.com/sample-request/59920-global-colorectal-cancer-drugs-market-2015-2019
2)
Analysis of this report
Technavio's analysts forecast the
global colorectal cancer drugs market to grow at a CAGR of 3.62% over the
period 2014-2019.
3)
Covered in this Report
This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of colorectal cancer.
Based on the type of molecule, the market is grouped into two categories:
• Biologics
• Small molecules
Based on the route of administration, the market is grouped into two categories:
• Oral
• Parenteral
This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019 in the following regions:
• Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil
• EMEA: The principal countries focused upon in this region are the UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE. Germany, Italy, and the UK are the leading European countries in terms of elderly population
• APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors as well as the competitive performances of their product portfolios in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market.
Technavio's report, Global Colorectal Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global colorectal cancer drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Amgen
• Bayer
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Merck Serono
Other Prominent Vendors
• Accord Healthcare
• Advenchen Laboratories
• Aeterna Zentaris
• AstraZeneca
• Bavarian Nordic
• Biothera
• Boehringer Ingelheim
• Daiichi Sankyo
• Debiopharm
• Eisai
• Eli Lilly
• Immodulon Therapeutics
• Mologen
• Mylan
• Nektar Therapeutics
• Oncothyreon
• Otsuka Pharmaceutical
• Precision Biologics
• Sun Pharmaceutical
• Symphogen
• Taiho
• Takeda
• Teva
• ThromboGenics
• Xbiotech
• Yakult Honsha
Market Driver
• Increase in population of patients
• For a full, detailed list, view our report
Market Challenge
• Loss of patent exclusivity
• For a full, detailed list, view our report
Market Trend
• Dominance of biologics
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of colorectal cancer.
Based on the type of molecule, the market is grouped into two categories:
• Biologics
• Small molecules
Based on the route of administration, the market is grouped into two categories:
• Oral
• Parenteral
This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019 in the following regions:
• Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil
• EMEA: The principal countries focused upon in this region are the UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE. Germany, Italy, and the UK are the leading European countries in terms of elderly population
• APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors as well as the competitive performances of their product portfolios in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market.
Technavio's report, Global Colorectal Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global colorectal cancer drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Amgen
• Bayer
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Merck Serono
Other Prominent Vendors
• Accord Healthcare
• Advenchen Laboratories
• Aeterna Zentaris
• AstraZeneca
• Bavarian Nordic
• Biothera
• Boehringer Ingelheim
• Daiichi Sankyo
• Debiopharm
• Eisai
• Eli Lilly
• Immodulon Therapeutics
• Mologen
• Mylan
• Nektar Therapeutics
• Oncothyreon
• Otsuka Pharmaceutical
• Precision Biologics
• Sun Pharmaceutical
• Symphogen
• Taiho
• Takeda
• Teva
• ThromboGenics
• Xbiotech
• Yakult Honsha
Market Driver
• Increase in population of patients
• For a full, detailed list, view our report
Market Challenge
• Loss of patent exclusivity
• For a full, detailed list, view our report
Market Trend
• Dominance of biologics
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Complete
Report: https://www.wiseguyreports.com/reports/59920-global-colorectal-cancer-drugs-market-2015-2019
Table of Contents
01 Executive Summary
2 List of Abbreviations
3 Scope of the Report
03.1
Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Pathophysiology
06.3 Epidemiology
06.4 Diagnosis
06.5 Staging
06.5.1 Staging: Colon Cancer
06.5.2 Staging: Rectal Cancer
06.6 Management
06.7 Economic Burden
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.2.1 Colorectal Cancer Drugs Market in US
07.2.2 Colorectal Cancer Drugs Market in Germany
07.2.3 Colorectal Cancer Drugs Market in Spain
07.2.4 Colorectal Cancer Drugs Market in Japan
07.2.5 Colorectal Cancer Drugs Market in China
07.3 Five Forces Analysis
08. Market Segmentation by Type of Molecules
08.1 Small molecules
08.2 Biologics
09. Market Segmentation by Route of Administration
09.1 Oral
09.2 Parenteral
10. Geographical Segmentation
10.1 Colorectal Cancer Drugs Market in Americas
10.1.1 Market Size and Forecast
10.2 Colorectal Cancer Drugs Market in EMEA
10.2.1 Market Size and Forecast
10.3 Colorectal Cancer Drugs Market in APAC
10.3.1 Market Size and Forecast
11. Key Leading Countries
11.1 US
11.2 Japan
11.3 Germany
11.4 Spain
11.5 China
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Competitive Assessment of Top Drugs for Colorectal Cancer
19.2.2 F. Hoffmann-La Roche
19.2.3 Merck Serono
19.2.4 Bristol-Myers Squibb
19.2.5 Amgen
19.2.6 Sanofi
19.2.7 Bayer
19.3 Other and Future Prominent Vendors
20. Key Takeaways
21. Key Vendor Analysis
21.1 Amgen
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Product Portfolio by Revenue 2013
21.1.5 Business Segmentation by Revenue 2012 and 2013
21.1.6 Geographical Segmentation by Revenue 2013
21.1.7 Business Strategy
21.1.8 Recent Developments
21.1.9 SWOT Analysis
21.2 Bayer
21.2.1 Key facts
21.2.2 Business overview
21.2.3 Business segmentation by revenue 2014
21.2.4 Business segmentation by revenue 2013 and 2014
21.2.5 Geographical segmentation by revenue 2014
21.2.6 Business strategy
21.2.7 Recent developments
21.2.8 SWOT analysis
21.3 Bristol-Myers Squibb Co.
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Key Product Offerings
21.3.4 Revenue by Geography
21.3.5 Business Strategy
21.3.6 Key Information
21.3.7 SWOT Analysis
21.4 F. Hoffmann-La Roche Ltd.
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Sales by Geography
21.4.6 Business Strategy
21.4.7 Key Information
21.4.8 SWOT Analysis
21.5 Merck Serono
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Geographical Segmentation by Revenue 2013
21.5.4 Business Strategy
21.5.5 Recent Developments
21.5.6 SWOT Analysis
21.6 Sanofi SA
21.6.1 Key Facts
21.6.2 Business Description
21.6.3 Business Segmentation
21.6.4 Revenue by Business Segmentation
21.6.5 Revenue Comparison 2012 and 2013
21.6.6 Sales by Geography
21.6.7 Business Strategy
21.6.8 Key Developments
21.6.9 SWOT Analysis
22. Other Reports in this Series
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Pathophysiology
06.3 Epidemiology
06.4 Diagnosis
06.5 Staging
06.5.1 Staging: Colon Cancer
06.5.2 Staging: Rectal Cancer
06.6 Management
06.7 Economic Burden
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.2.1 Colorectal Cancer Drugs Market in US
07.2.2 Colorectal Cancer Drugs Market in Germany
07.2.3 Colorectal Cancer Drugs Market in Spain
07.2.4 Colorectal Cancer Drugs Market in Japan
07.2.5 Colorectal Cancer Drugs Market in China
07.3 Five Forces Analysis
08. Market Segmentation by Type of Molecules
08.1 Small molecules
08.2 Biologics
09. Market Segmentation by Route of Administration
09.1 Oral
09.2 Parenteral
10. Geographical Segmentation
10.1 Colorectal Cancer Drugs Market in Americas
10.1.1 Market Size and Forecast
10.2 Colorectal Cancer Drugs Market in EMEA
10.2.1 Market Size and Forecast
10.3 Colorectal Cancer Drugs Market in APAC
10.3.1 Market Size and Forecast
11. Key Leading Countries
11.1 US
11.2 Japan
11.3 Germany
11.4 Spain
11.5 China
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Competitive Assessment of Top Drugs for Colorectal Cancer
19.2.2 F. Hoffmann-La Roche
19.2.3 Merck Serono
19.2.4 Bristol-Myers Squibb
19.2.5 Amgen
19.2.6 Sanofi
19.2.7 Bayer
19.3 Other and Future Prominent Vendors
20. Key Takeaways
21. Key Vendor Analysis
21.1 Amgen
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Product Portfolio by Revenue 2013
21.1.5 Business Segmentation by Revenue 2012 and 2013
21.1.6 Geographical Segmentation by Revenue 2013
21.1.7 Business Strategy
21.1.8 Recent Developments
21.1.9 SWOT Analysis
21.2 Bayer
21.2.1 Key facts
21.2.2 Business overview
21.2.3 Business segmentation by revenue 2014
21.2.4 Business segmentation by revenue 2013 and 2014
21.2.5 Geographical segmentation by revenue 2014
21.2.6 Business strategy
21.2.7 Recent developments
21.2.8 SWOT analysis
21.3 Bristol-Myers Squibb Co.
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Key Product Offerings
21.3.4 Revenue by Geography
21.3.5 Business Strategy
21.3.6 Key Information
21.3.7 SWOT Analysis
21.4 F. Hoffmann-La Roche Ltd.
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Sales by Geography
21.4.6 Business Strategy
21.4.7 Key Information
21.4.8 SWOT Analysis
21.5 Merck Serono
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Geographical Segmentation by Revenue 2013
21.5.4 Business Strategy
21.5.5 Recent Developments
21.5.6 SWOT Analysis
21.6 Sanofi SA
21.6.1 Key Facts
21.6.2 Business Description
21.6.3 Business Segmentation
21.6.4 Revenue by Business Segmentation
21.6.5 Revenue Comparison 2012 and 2013
21.6.6 Sales by Geography
21.6.7 Business Strategy
21.6.8 Key Developments
21.6.9 SWOT Analysis
22. Other Reports in this Series
Continued……………
Continued………………….
CONTACT US:
NORAH TRENT
Partner Relations & Marketing
Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Comments
Post a Comment